Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
August 07, 2023 05:00 ET
|
First Light Acquisition Group
RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, today announced that the U.S. Securities and...
KAIST and Checkmate Capital Complete Investment in Bredis Healthcare
May 25, 2023 18:00 ET
|
Checkmate Capital
Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea Further Announcement of Bredis’ Agreements with Major University Hospitals SEOUL,...
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 08, 2022 16:10 ET
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics
August 15, 2022 23:41 ET
|
Endure Biotherapeutics, Inc.
San Diego, Aug. 15, 2022 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics Zarrinpar...
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
April 07, 2022 11:00 ET
|
NeuroSigma, Inc.
Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
January 11, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
January 05, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics and Biomarkers
January 04, 2022 08:33 ET
|
Inotiv, Inc.
-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions -- -- Expected to enhance scale, broaden customer base...
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
January 03, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...